| Pactimibe | cardiovascular prevention, in all type of patients | vs placebo | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Non fatal stroke | no data | | Non fatal MI | no data | | stroke (fatal and non fatal) | no data | | cardiovascular events | no data | | Carotid revascularization | no data | | Coronary revascularization | no data | | change in mean CIMT | no data | | change in maximum CIMT | no data | | cardiovascular events including revascularization | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CAPTIVATE, 2009 | pactimibe 100mg daily | placebo | patients with familial hypercholesterolemia and carotid atherosclerosis | | ACTIVATE, 2006 | pactimibe 100 mg daily | placebo | patients with angiographicallydocumented coronary disease |
|
